Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model

Eric Rodenberg, Ali Azhdarinia, Zawaunyka W. Lazard, Mary Hall, Sun Kuk Kwon, Nathaniel Wilganowski, Elizabeth Salisbury, Maria Merched-Sauvage, Elizabeth A. Olmsted-Davis, Eva M. Sevick-Muraca, Alan R. Davis

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Heterotopic ossification (HO) is a serious disorder that occurs when there is aberrant bone morphogenic protein (BMP) signaling in soft tissues. Currently, there are no methods to detect HO before mineralization occurs. Yet once mineralization occurs, there are no effective treatments, short of surgery, to reverse HO. Herein, we used in vivo molecular imaging and confirmatory ex vivo tissue analyses of an established murine animal model of BMP-induced HO to show that matrix metalloproteinase-9 (MMP-9) can be detected as an early-stage biomarker before mineralization. Ex vivo analyses show that active MMP-9 protein is significantly elevated within tissues undergoing HO as early as 48h after BMP induction, with its expression co-localizing to nerves and vessels. In vivo molecular imaging with a dual-labeled near-infrared fluorescence and micro-positron emission tomography (μPET) agent specific to MMP-2/-9 expression paralleled the ex vivo observations and reflected the site of HO formation as detected from microcomputed tomography 7 days later. The results suggest that the MMP-9 is a biomarker of the early extracellular matrix (ECM) re-organization and could be used as an in vivo diagnostic with confirmatory ex vivo tissue analysis for detecting HO or conversely for monitoring the success of tissue-engineered bone implants that employ ECM biology for engraftment.

Original languageEnglish (US)
Pages (from-to)2487-2496
Number of pages10
JournalTissue Engineering - Part A
Volume17
Issue number19-20
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Heterotopic Ossification
Matrix Metalloproteinase 9
Tissue
Bone
Proteins
Molecular imaging
Biomarkers
Bone and Bones
Molecular Imaging
Extracellular Matrix
Positron emission tomography
Matrix Metalloproteinases
Surgery
X-Ray Microtomography
Tomography
Animals
Fluorescence
Metalloproteases
Positron-Emission Tomography
Infrared radiation

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials
  • Medicine(all)

Cite this

Rodenberg, E., Azhdarinia, A., Lazard, Z. W., Hall, M., Kwon, S. K., Wilganowski, N., ... Davis, A. R. (2011). Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model. Tissue Engineering - Part A, 17(19-20), 2487-2496. https://doi.org/10.1089/ten.tea.2011.0007

Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model. / Rodenberg, Eric; Azhdarinia, Ali; Lazard, Zawaunyka W.; Hall, Mary; Kwon, Sun Kuk; Wilganowski, Nathaniel; Salisbury, Elizabeth; Merched-Sauvage, Maria; Olmsted-Davis, Elizabeth A.; Sevick-Muraca, Eva M.; Davis, Alan R.

In: Tissue Engineering - Part A, Vol. 17, No. 19-20, 01.10.2011, p. 2487-2496.

Research output: Contribution to journalArticle

Rodenberg, E, Azhdarinia, A, Lazard, ZW, Hall, M, Kwon, SK, Wilganowski, N, Salisbury, E, Merched-Sauvage, M, Olmsted-Davis, EA, Sevick-Muraca, EM & Davis, AR 2011, 'Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model', Tissue Engineering - Part A, vol. 17, no. 19-20, pp. 2487-2496. https://doi.org/10.1089/ten.tea.2011.0007
Rodenberg E, Azhdarinia A, Lazard ZW, Hall M, Kwon SK, Wilganowski N et al. Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model. Tissue Engineering - Part A. 2011 Oct 1;17(19-20):2487-2496. https://doi.org/10.1089/ten.tea.2011.0007
Rodenberg, Eric ; Azhdarinia, Ali ; Lazard, Zawaunyka W. ; Hall, Mary ; Kwon, Sun Kuk ; Wilganowski, Nathaniel ; Salisbury, Elizabeth ; Merched-Sauvage, Maria ; Olmsted-Davis, Elizabeth A. ; Sevick-Muraca, Eva M. ; Davis, Alan R. / Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model. In: Tissue Engineering - Part A. 2011 ; Vol. 17, No. 19-20. pp. 2487-2496.
@article{a350b286fe8543118b0f64859b67e7ca,
title = "Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model",
abstract = "Heterotopic ossification (HO) is a serious disorder that occurs when there is aberrant bone morphogenic protein (BMP) signaling in soft tissues. Currently, there are no methods to detect HO before mineralization occurs. Yet once mineralization occurs, there are no effective treatments, short of surgery, to reverse HO. Herein, we used in vivo molecular imaging and confirmatory ex vivo tissue analyses of an established murine animal model of BMP-induced HO to show that matrix metalloproteinase-9 (MMP-9) can be detected as an early-stage biomarker before mineralization. Ex vivo analyses show that active MMP-9 protein is significantly elevated within tissues undergoing HO as early as 48h after BMP induction, with its expression co-localizing to nerves and vessels. In vivo molecular imaging with a dual-labeled near-infrared fluorescence and micro-positron emission tomography (μPET) agent specific to MMP-2/-9 expression paralleled the ex vivo observations and reflected the site of HO formation as detected from microcomputed tomography 7 days later. The results suggest that the MMP-9 is a biomarker of the early extracellular matrix (ECM) re-organization and could be used as an in vivo diagnostic with confirmatory ex vivo tissue analysis for detecting HO or conversely for monitoring the success of tissue-engineered bone implants that employ ECM biology for engraftment.",
author = "Eric Rodenberg and Ali Azhdarinia and Lazard, {Zawaunyka W.} and Mary Hall and Kwon, {Sun Kuk} and Nathaniel Wilganowski and Elizabeth Salisbury and Maria Merched-Sauvage and Olmsted-Davis, {Elizabeth A.} and Sevick-Muraca, {Eva M.} and Davis, {Alan R.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1089/ten.tea.2011.0007",
language = "English (US)",
volume = "17",
pages = "2487--2496",
journal = "Tissue Engineering - Part A.",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "19-20",

}

TY - JOUR

T1 - Matrix metalloproteinase-9 is a diagnostic marker of heterotopic ossification in a murine model

AU - Rodenberg, Eric

AU - Azhdarinia, Ali

AU - Lazard, Zawaunyka W.

AU - Hall, Mary

AU - Kwon, Sun Kuk

AU - Wilganowski, Nathaniel

AU - Salisbury, Elizabeth

AU - Merched-Sauvage, Maria

AU - Olmsted-Davis, Elizabeth A.

AU - Sevick-Muraca, Eva M.

AU - Davis, Alan R.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Heterotopic ossification (HO) is a serious disorder that occurs when there is aberrant bone morphogenic protein (BMP) signaling in soft tissues. Currently, there are no methods to detect HO before mineralization occurs. Yet once mineralization occurs, there are no effective treatments, short of surgery, to reverse HO. Herein, we used in vivo molecular imaging and confirmatory ex vivo tissue analyses of an established murine animal model of BMP-induced HO to show that matrix metalloproteinase-9 (MMP-9) can be detected as an early-stage biomarker before mineralization. Ex vivo analyses show that active MMP-9 protein is significantly elevated within tissues undergoing HO as early as 48h after BMP induction, with its expression co-localizing to nerves and vessels. In vivo molecular imaging with a dual-labeled near-infrared fluorescence and micro-positron emission tomography (μPET) agent specific to MMP-2/-9 expression paralleled the ex vivo observations and reflected the site of HO formation as detected from microcomputed tomography 7 days later. The results suggest that the MMP-9 is a biomarker of the early extracellular matrix (ECM) re-organization and could be used as an in vivo diagnostic with confirmatory ex vivo tissue analysis for detecting HO or conversely for monitoring the success of tissue-engineered bone implants that employ ECM biology for engraftment.

AB - Heterotopic ossification (HO) is a serious disorder that occurs when there is aberrant bone morphogenic protein (BMP) signaling in soft tissues. Currently, there are no methods to detect HO before mineralization occurs. Yet once mineralization occurs, there are no effective treatments, short of surgery, to reverse HO. Herein, we used in vivo molecular imaging and confirmatory ex vivo tissue analyses of an established murine animal model of BMP-induced HO to show that matrix metalloproteinase-9 (MMP-9) can be detected as an early-stage biomarker before mineralization. Ex vivo analyses show that active MMP-9 protein is significantly elevated within tissues undergoing HO as early as 48h after BMP induction, with its expression co-localizing to nerves and vessels. In vivo molecular imaging with a dual-labeled near-infrared fluorescence and micro-positron emission tomography (μPET) agent specific to MMP-2/-9 expression paralleled the ex vivo observations and reflected the site of HO formation as detected from microcomputed tomography 7 days later. The results suggest that the MMP-9 is a biomarker of the early extracellular matrix (ECM) re-organization and could be used as an in vivo diagnostic with confirmatory ex vivo tissue analysis for detecting HO or conversely for monitoring the success of tissue-engineered bone implants that employ ECM biology for engraftment.

UR - http://www.scopus.com/inward/record.url?scp=80053128756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053128756&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2011.0007

DO - 10.1089/ten.tea.2011.0007

M3 - Article

VL - 17

SP - 2487

EP - 2496

JO - Tissue Engineering - Part A.

JF - Tissue Engineering - Part A.

SN - 1937-3341

IS - 19-20

ER -